Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: Yale Cancer Center, Yale University, University of California, Los Angeles, University of Kansas Medical Center, University of Washington, Fred Hutch Cancer Center, The University of Texas Southwestern Medical Center, Roswell Park Comprehensive Cancer Center, Virginia Cancer Specialists, Minnesota Oncology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2990549202